Back to the complete issue
Sunday, 8 January 2017

Pharma producers reportedly refuse chronic disease-treatment classification, demand price increases across the board

International pharma producers have reportedly refused the government’s proposal to only increase prices medications for non-chronic diseases, Al Mal reported. International producers have reportedly submitted the government a list of all their products, expecting their prices to increase by 20% across the board, regardless of whether or not they are for chronic diseases. There were reports last week of a dispute over how to define chronic diseases, after the Health Ministry said it will not allow any price increases for medications treating them. If the government insists on freezing the prices of chronic disease treatments, international pharma producers will halt all negotiations with the government and possibly freeze production in Egypt, a source said. The government’s classification makes “no sense,” as “90%” of all medications on the market are for chronic diseases, the source added.

What’s the government offering? The last agreement reached between the government reportedly allowed for increasing the prices of 15% of domestically-produced medications in tiers ranging from 50% for those selling for EGP1-50, to 40% for those selling for EGP 50-100, and by 30% for those that are more expensive than EGP 100. It also allowed for increasing prices of 20% of imported medications raising those selling for under EGP 50 by 50% and by 40% for more expensive ones.

The Health Ministry could budge? Sources tell Al Borsa that the health ministry might be allowing price increases for some of the medications used to treat chronic diseases after all. The committee concerned with studying the price hike will be making the decision after conducting separate reviews of each of the lists submitted by companies to the ministry last week. The story gives no sense of timeline.

Enterprise is a daily publication of Enterprise Ventures LLC, an Egyptian limited liability company (commercial register 83594), and a subsidiary of Inktank Communications. Summaries are intended for guidance only and are provided on an as-is basis; kindly refer to the source article in its original language prior to undertaking any action. Neither Enterprise Ventures nor its staff assume any responsibility or liability for the accuracy of the information contained in this publication, whether in the form of summaries or analysis. © 2022 Enterprise Ventures LLC.

Enterprise is available without charge thanks to the generous support of HSBC Egypt (tax ID: 204-901-715), the leading corporate and retail lender in Egypt; EFG Hermes (tax ID: 200-178-385), the leading financial services corporation in frontier emerging markets; SODIC (tax ID: 212-168-002), a leading Egyptian real estate developer; SomaBay (tax ID: 204-903-300), our Red Sea holiday partner; Infinity (tax ID: 474-939-359), the ultimate way to power cities, industries, and homes directly from nature right here in Egypt; CIRA (tax ID: 200-069-608), the leading providers of K-12 and higher level education in Egypt; Orascom Construction (tax ID: 229-988-806), the leading construction and engineering company building infrastructure in Egypt and abroad; Moharram & Partners (tax ID: 616-112-459), the leading public policy and government affairs partner; Palm Hills Developments (tax ID: 432-737-014), a leading developer of commercial and residential properties; Mashreq (tax ID: 204-898-862), the MENA region’s leading homegrown personal and digital bank; Industrial Development Group (IDG) (tax ID:266-965-253), the leading builder of industrial parks in Egypt; Hassan Allam Properties (tax ID:  553-096-567), one of Egypt’s most prominent and leading builders; and Saleh, Barsoum & Abdel Aziz (tax ID: 220-002-827), the leading audit, tax and accounting firm in Egypt.